• Camp4 Therapeutics posted a net loss of $18.3 million, widening from $12.4 million.
• Research and collaboration revenue rose to $1.29 million from $858,000, while research and development expense was $10.2 million versus $10.1 million.
• Cash and cash equivalents fell to $99.2 million from $109.5 million; cash runway expected into 2028.
• Submitted first clinical trial regulatory filing for CMP-002 in Australia, targeting initiation of a global Phase 1/2 trial in SYNGAP1 patients in 2H 2026.
• EMA granted Orphan Designation for CMP-002; Orphan Drug Designation submission filed with FDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Camp4 Therapeutics Corporation published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.